Option chain shows key data for PureTech Health's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PureTech Health.

PureTech Health (NASDAQ:PRTC) Stock, Option Chain

PureTech Health

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

PRTC

Biotech

News

Health Care

Movers

General

PureTech Health&#39;s Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function improvement and dose-dependent benefits.

PureTech&#39;s Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Markets

Trading Ideas

AKTS

ATCH

BTCT

EWTX

FUFU

IPHA

KPTI

KTOS

LAES

RDZN

SGMT

SIDU

SMCI

STEC

TNXP

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

BristolMeyersSquibb.Courtesyof.02-LVL-Exterior-Sign-101520-media

Large Cap

Bristol Myers Squibb&#39;s Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without blocking D2 receptors.

Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb&#39;s Cobenfy As First New Class Of Treatment In More Than 3 Decades

PureTech Health plc - American Depositary Shares

PureTech Health PLC

Press Releases

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Appoints UBS as UK Corporate Broker

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

PureTech to Present at the Leerink Partners Global Healthcare Conference

Leerink Partners

Piper Sandler

SVB Leerink

Comments

PureTech Health

PureTech Health (PRTC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga